Literature DB >> 15208672

Activated p53 suppresses the histone methyltransferase EZH2 gene.

Xiaohu Tang1, Michael Milyavsky, Igor Shats, Neta Erez, Naomi Goldfinger, Varda Rotter.   

Abstract

Replicative senescence is an irreversible cell cycle arrest that limits the proliferation of damaged cells and may be an important tumor suppression mechanism in vivo. This process is regulated at critical steps by the tumor suppressor p53. To identify genes that may regulate the senescence process, we performed cDNA microarray analysis of gene expression in senescent, young proliferating, and hTERT-immortalized primary human fibroblasts. The histone methyltransferase (HMTase), EZH2, was specifically downregulated in senescent cells. Activated p53 suppressed EZH2 gene expression through repression of the EZH2 gene promoter. This activity of p53 requires intact p53 transactivation and DNA binding domains. Furthermore, the repression of EZH2 promoter by p53 is dependent on p53 transcriptional target p21(Waf1) inactivating RB/E2F pathways. In addition, the knockdown of EZH2 expression retards cell proliferation and induces G2/M arrest. We suggest that the p53-dependent suppression of EZH2 expression is a novel pathway that contributes to p53-mediated G2/M arrest. EZH2 associated complex possesses HMTase activity and is involved in epigenetic regulation. Activated p53 suppresses EZH2 expression, suggesting a further role for p53 in epigenetic regulation and in the maintenance of genetic stability. Suppression of EZH2 expression in tumors by p53 may lead to novel approaches to control cancer progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208672     DOI: 10.1038/sj.onc.1207706

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  71 in total

1.  Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2.

Authors:  Meilan He; Wei Zhang; Thomas Bakken; Melissa Schutten; Zsolt Toth; Jae U Jung; Parkash Gill; Mark Cannon; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

2.  The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion.

Authors:  Leonie M Kamminga; Leonid V Bystrykh; Aletta de Boer; Sita Houwer; José Douma; Ellen Weersing; Bert Dontje; Gerald de Haan
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 3.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

4.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

5.  EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo.

Authors:  Hui Xia; Chang-Hai Yu; Yiming Zhang; Jianqi Yu; Jie Li; Wen Zhang; Baoshi Zhang; Yingjie Li; Nannan Guo
Journal:  Oncol Lett       Date:  2012-04-26       Impact factor: 2.967

6.  c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.

Authors:  Wen Hao Neo; Jun Feng Lim; Raelene Grumont; Steve Gerondakis; I-Hsin Su
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

Review 7.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

8.  Retinoblastoma-binding Protein 4-regulated Classical Nuclear Transport Is Involved in Cellular Senescence.

Authors:  Akira Tsujii; Yoichi Miyamoto; Tetsuji Moriyama; Yuko Tsuchiya; Chikashi Obuse; Kenji Mizuguchi; Masahiro Oka; Yoshihiro Yoneda
Journal:  J Biol Chem       Date:  2015-10-21       Impact factor: 5.157

9.  MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Authors:  Paul Cao; Zhiyong Deng; Meimei Wan; Weiwei Huang; Scott D Cramer; Jianfeng Xu; Ming Lei; Guangchao Sui
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

10.  Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Authors:  Nina Wagener; Stephan Macher-Goeppinger; Maria Pritsch; Johannes Hüsing; Karin Hoppe-Seyler; Peter Schirmacher; Jesco Pfitzenmaier; Axel Haferkamp; Felix Hoppe-Seyler; Markus Hohenfellner
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.